US2697961082 - Common Stock
After the closing bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
As the regular session of the US market concludes on Thursday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Which stocks are moving after the closing bell on Wednesday?
WOODCLIFF LAKE, N.J., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (the “Company” or “Eagle”) today announced that it...
WOODCLIFF LAKE, N.J., May 22, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (the “Company” or “Eagle”) today announced that it...
-- Single dose, IV amisulpride (10 mg) results in sustained antiemetic effect with supratherapeutic plasma levels of drug being maintained for at least 24...
WOODCLIFF LAKE, N.J., April 12, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (the “Company”) today announced that it received a...
Eagle Pharmaceuticals (EGRX) plans to cut 36% of its workforce to improve operational efficiencies and reduce sales and marketing expenses. Read more here.
/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Eagle Pharmaceuticals, Inc. ("Eagle...
/PRNewswire/ -- Attention Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals") (NASDAQ: EGRX) shareholders: The Law Offices of Vincent Wong announce that a...
/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ:...
WHY: NEW YORK, NY - (NewMediaWire) - February 06, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) between August 8, 2023 and November 28, 2023, both dates inclusive (the “Class Period”), of the important February 9, 2024 lead plaintiff deadline.
WHY: NEW YORK, NY - (NewMediaWire) - February 06, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) between August 8, 2023 and November 28, 2023, both dates inclusive (the “Class Period”), of the important February 9, 2024 lead plaintiff deadline.
/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company") (NASDAQ: EGRX) of a class...
/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) between...
WHY: NEW YORK, NY - (NewMediaWire) - February 02, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) between August 8, 2023 and November 28, 2023, both dates inclusive (the “Class Period”), of the important February 9, 2024 lead plaintiff deadline.
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Eagle Pharmaceuticals, Inc. ("Eagle...
/PRNewswire/ -- Attention Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals") (NASDAQ: EGRX) shareholders: The Law Offices of Vincent Wong announce that a...
/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company") (NASDAQ: EGRX) of a class...
WHY: NEW YORK, NY - (NewMediaWire) - January 29, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) between August 8, 2023 and November 28, 2023, both dates inclusive (the “Class Period”), of the important February 9, 2024 lead plaintiff deadline.
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
WHY: NEW YORK, NY - (NewMediaWire) - January 28, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) between August 8, 2023 and November 28, 2023, both dates inclusive (the “Class Period”), of the important February 9, 2024 lead plaintiff deadline.
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) between...
/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Eagle Pharmaceuticals, Inc. ("Eagle...
/PRNewswire/ -- Attention Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals") (NASDAQ: EGRX) shareholders: The Law Offices of Vincent Wong announce that a...